A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Conditions

• Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Unconjugated belantamab antibody — DRUG
  Unconjugated belantamab antibody will be administered.
• Belantamab mafodotin — DRUG
  Belantamab mafodotin will be administered.
• Unconjugated belantamab antibody and belantamab mafodotin — DRUG
  Unconjugated belantamab antibody and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
• Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone — DRUG
  Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone will be administered.

Study Details

The study consists of three parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of unconjugated belantamab antibody in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.

Key Dates

First listed

Feb 6, 2023

Start date

Jun 14, 2023

Status verified

Jul 2026

Primary completion

Aug 3, 2028

Completion

Aug 3, 2028

Study Design

Enrollment

123 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part 1: Dose escalation and expansion of the unconjugated belantamab antibody monotherapy
  Unconjugated belantamab antibody will be administered in participants with RRMM until progressive disease (PD)
• Experimental: Part 2:Unconjugated belantamab antibody and belantamab mafodotin-given separately dose range finding
  Participants with RRMM will receive unconjugated belantamab antibody and belantamab mafodotin
• Experimental: Part 3: Unconjugated belantamab antibody +pomalidomide/dexamethasone in 2L+ RRMM
  Participants with RRMM will receive Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone.
• Experimental: Part 1b: Optional belantamab mafodotin
  Participants enrolled in Part 1 and Part 2 will be dosed until PD after which they will have the option to receive treatment with single agent belantamab mafodotin.

Primary Outcome Measure

Part 1, 2 and 3: Number of Participants with any Adverse Event [ Time Frame: Up to 52 months ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (8)

Find similar trials in Bullhead City, AZ

Related Studies

• Collection of Tissue Samples for Cancer Research
  Recruiting · National Cancer Institute (NCI) · Atlanta, Georgia
• Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
  Recruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
  Recruiting · Wake Forest University Health Sciences · Winston-Salem, North Carolina
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado